reports
- Jonathan Moreland
- Dave Nicoski
- Ross LaDuke
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
PRTA PROTHENA CORP. PLC
NTRS NORTHERN TRUST CORPORATION
KMB KIMBERLY-CLARK CORPORATION
KHC KRAFT HEINZ COMPANY
CRK COMSTOCK RESOURCES INC.
COG CABOT OIL & GAS CORPORATION
BGS B&G FOODS INC.
AR ANTERO RESOURCES CORPORATION
AAP ADVANCE AUTO PARTS INC.
REI REIBEL
ELY CALLAWAY GOLF COMPANY
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
TG TREDEGAR CORP.
NNI NELNET INC. CLASS A
AA ALCOA CORPORATION
CTVA CORTEVA INC
RVLV REVOLVE GROUP
BALY BALLYS CORPORATION
VHI VALHI INC.
APA APA CORPORATION
SWIM LATHAM GROUP INC
ALTG ALTA EQUIP GROUP INC
DO DIAMOND OFFSHORE DRILLING INC.
XPOF XPONENTIAL FITNESS INC
AVO THE AVEON GROUP LP
Prothena to Report Third Quarter 2022 Financial Results on November 3r...
Prothena to Report Third Quarter 2022 Financial Results on November 3rd DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2022 financial results on Thursday, November 3, 2022 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this fi...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PRTA PROTHENA CORP. PLC
PROV PROVIDENT FINANCIAL HOLDINGS INC.
NRC NATIONAL RESEARCH CORPORATION
AMOT ALLIED MOTION TECHNOLOGIES
PEN PENUMBRA INC.
CAPR CAPRICOR THERAPEUTICS
IBEX IBEX
POSH POSHMARK
TERN TERNS PHARMACEUTICALS
CANO CANO HEALTH INC
TMCI TREACE MED CONCEPTS INC
RIVN RIVIAN AUTOMOTIVE INC
TRDA ENTRADA THERAPEUTICS INC
RXRX RECURSION PHARMACEUTICALS INC
RLYB RALLYBIO CORP
VIGL VIGIL NEUROSCIENCE INC
MRNS MARINUS PHARMACEUTICALS INC
OMGA OMEGA THERAPEUTICS INC
RLMD RELMADA THERAPEUTICS INC
Prothena to Participate in Upcoming Healthcare Conferences
Prothena to Participate in Upcoming Healthcare Conferences DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following upcoming investor conferences: Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 1x1 investor meetings will be heldMorgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September ...
Prothena Announces Appointment of Biotechnology Industry Leader Helen ...
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Helen S. Kim, MBA, to its Board of Directors. Ms. Kim has over 27 years of experience in leadership roles in biotechnology, including her previous role as Executive Vice President of Business Development at Kite Pharma, Inc....
Prothena Reports Second Quarter 2022 Financial Results and Business Hi...
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 2022; quarter-end cash and restricted cash position was $510.1 millionBroad Alzheimer’s disease portfolio continues to advance: FDA Fast Track designation granted in April for PRX012, a potential best-in-class, next-generation anti-Aβ antibody therapy; topline data expected by year-end from Phase 1 clinical study of PRX005, a potential best-in-class MTBR-specific anti-tau antib...
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individual hired by the Company an option to purchase 35,000 ordinary shares of the Company. The option has an exercise price per share equal to ...
Prothena to Report Second Quarter 2022 Financial Results on August 8th
Prothena to Report Second Quarter 2022 Financial Results on August 8th DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first six months of 2022 financial results on Monday, August 8, 2022 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financi...
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, July 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring two new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 50,000 ordinary shares of the Company. The options have an exercise pr...
Prothena to Participate in Jefferies Healthcare Conference
Prothena to Participate in Jefferies Healthcare Conference DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday June 8, 2022 at 8:30 AM ET. A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at . Followi...
Prothena Reports First Quarter 2022 Financial Results and Business Hig...
Prothena Reports First Quarter 2022 Financial Results and Business Highlights Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-end cash and restricted cash position was $544.3 millionAdvanced PRX012, a potential best-in-class, subcutaneous treatment for Alzheimer’s disease, into a Phase 1 clinical study and received FDA Fast Track designation Multiple presentations at AD/PD 2022 highlighting depth of neurodegenerative portfolio targeting Alzheimer’s and Parkinson’s diseases DUBLIN, Ireland, May 05, 2022 (GLOBE NEWSWIRE) -- Prothena Corpo...
Prothena to Report First Quarter 2022 Financial Results on May 5th
Prothena to Report First Quarter 2022 Financial Results on May 5th DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 5. ...
Prothena Receives FDA Fast Track Designation for PRX012, a Next-Genera...
Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer’s disease DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that the U.S. Foo...
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Ant...
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer’s disease DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new ...
Prothena to Participate in Stifel 2022 Virtual CNS Days
Prothena to Participate in Stifel 2022 Virtual CNS Days DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Stifel 2022 Virtual CNS Days on Monday March 28, 2022 at 12:30 PM ET. A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at . Following ...
Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Pro...
Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022 Oral presentation on preclinical data demonstrates Prothena’s dual Aβ/tau vaccine, for the potential treatment and prevention of Alzheimer’s, generated anti-Aβ and anti-tau antibodies to enable phagocytosis of Aβ and to neutralize tauPreclinical data from poster presentation demonstrates that Prothena’s tandem C-terminal α-synuclein vaccine, for the potential treatment and prevention of Parkinson’s, produces robust binding to pathogenic α-synuclein and inhibition of uptake of soluble α-synuclein aggreg...
Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, ...
Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights Net cash used in operating and investing activities was $22.8 million in the fourth quarter and net cash provided by operating and investing activities was $92.0 million for the full year 2021; quarter-end cash and restricted cash position was $580.4 million Reached SPA agreement with FDA at p≤0.10 for confirmatory Phase 3 study of birtamimab and initiated the study in Mayo Stage IV patients with AL amyloidosis Received $80 million option payment from Bristol Myers S...
Prothena to Report Fourth Quarter and Full Year 2021 Financial Results...
Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022 DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022 after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at...
An unfavourable environment weighs on PROTHENA, which sees a downgrade...
The independent financial analyst theScreener just requalified the general evaluation of PROTHENA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date January 14, 2022, the closing...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.